More Videos
|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- A Goldman Trading Scandal?
- The Rising Mountain of Debt May Be the Next Crisis
- Cuddle Parties Heat Up
- Latvian Banker Taking Souls as Collateral
- Alaska Governor Sarah Palin Will Resign
- Malaysia PM Speaks to CNBC
- SEC May Reinstate Rules for Short-Selling Stocks
- Your First Move For Monday July 6th
- Market 360: The Week's Best & Worst
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- Plan to Sell General Motors' Assets Is Approved
- BOJ Shirakawa: Japan Corporate Finance Still Tight
- China Reassures on Dollar Debate Before G8
- Obama Heads to Moscow for 'Reset' Summit
- UK Spy Chief's Wife Posts Life on Facebook
- Alcoa to Post Loss — What Does This Mean?
- A Goldman Trading Scandal?
- Partner Re to Buy Paris Re in $2 Billion Deal
- Happiness is ... Living Green in Costa Rica
RSS FEED
Text Size 
 |
CNBC.com |
] was halted for news pending. Then, right after the bell the company issued this press release announcing the Food and Drug Administration has granted "accelerated approval" to Genentech's Avastin for use on breast cancer. The announcement says the FDA will review the results of two more clinical trials before it might grant full approval of the drug and that Genentech will turn in the findings of three other studies.
So, what in the heck is accelerated approval? Here's an explanation from the FDA's web site. I think the most significant part is the last line:
"If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit for patients, FDA has regulatory procedures in place that could lead to removing the drug from the market."
Again, based on what's in the Genentech press release it sounds like the FDA will look at two confirmatory trials.
The stock resumed trading after hours and spiked about nine percent. Mark Schoenebaum at Bear Stearns has already sent out a blitz email to clients saying, "We include only very modest growth for Avastin breast cancer sales in our models. We expect the stock to open up $4+ on Monday. Back to you (the firm's clients) after we speak with the company."
We'll be speaking on Monday with the company in a First On CNBC interview with Dr. Susan Desmond-Hellmann, Genentech's President of Product Development and a former practicing oncologist who specialized in breast cancer. That's Monday at 8:30 am ET on "Squawk Box".
Schoenebaum or someone in his household owns DNA shares. As a reminder, he was on CNBC more than a week ago saying there was about a 55 perecent chance, in his opinion, of DNA winning. That was higher than most analysts placing odds. I guess it was a good call.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes